Ignite Creation Date:
2025-12-24 @ 3:05 PM
Ignite Modification Date:
2025-12-27 @ 4:50 AM
Study NCT ID:
NCT01863459
Status:
COMPLETED
Last Update Posted:
2017-08-02
First Post:
2013-05-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity
Sponsor:
Centre for Anxiety, Attention Deficit and Trauma, Ontario, Canada
Organization:
Study Overview
Official Title:
Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity
Status:
COMPLETED
Status Verified Date:
2017-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
1. To evaluate the safety, and efficacy of Lisdexamfetamine dimesylate in the treatment of outpatients with DSM-IV ADHD with anxiety and depressive disorder comorbidity, as well as to evaluate the effects on quality of life .
2. To evaluate the efficacy of Lisdexamfetamine dimesylate in the treatment of anxiety and depressive disorders which commonly occur with ADHD.
3. To examine the potential relationship between telomere length and Adult ADHD with comorbidity and the potential effect of treatment response.
4. To examine the potential associations with specific genes and Adult ADHD.
2. To evaluate the efficacy of Lisdexamfetamine dimesylate in the treatment of anxiety and depressive disorders which commonly occur with ADHD.
3. To examine the potential relationship between telomere length and Adult ADHD with comorbidity and the potential effect of treatment response.
4. To examine the potential associations with specific genes and Adult ADHD.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: